C4 Therapeutics, Inc. — Director's Dealing 2021

Apr 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-04-05

Reporting Person: Salter Malcolm (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-05	Common Stock	A	359	$37.51	Acquired	16353	Direct

Footnotes

F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 5, 2021.